Cohance Lifesciences Limited Itraconazole Export Data — India (DGFT 2022–2026)

Name: Cohance Lifesciences Limited Itraconazole Export Records India — #1 Exporter, 69 Shipments, $3.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Itraconazole

India Pharmaceutical Trade Intelligence

$27.4M285 Suppliers123 CountriesHS 30049099

ExportsIndia → UNITED STATES33.5%India → BRAZIL8.9%

ImportsITALY → India$138.3K UNITED STATES → India$21.6K

#1 Supplier: COHANCE LIFESCIENCES #1 Buyer: NEOETHICALS, S.A,

Cohance Lifesciences Limited — Itraconazole Exporter #1 | $3.5M Trade Value | TransData Nexus | TransData Nexus

Cohance Lifesciences Limited — Itraconazole Exporter Profile

Indian Pharmaceutical Exporter · #1 for Itraconazole · $3.5M export value · DGFT Verified

Cohance Lifesciences Limited is the #1 Indian exporter of Itraconazole with $3.5M in export value and 69 verified shipments. Cohance Lifesciences Limited holds a 12.6% market share in Itraconazole exports across 5 countries. The company exports 4 pharmaceutical products worth $13.6M across 4 therapeutic categories.

Cohance Lifesciences Limited — Itraconazole Export Profile: Buyers & Destinations

Cohance Lifesciences Limited Itraconazole export treemap — buyers and destination countries | TransData Nexus

Where Does Cohance Lifesciences Limited Export Itraconazole?

Country	Value	Shipments	Share
BRAZIL	$818.1K	20	34.7%
AUSTRALIA	$471.8K	16	20.0%
INDONESIA	$409.2K	14	17.4%
CANADA	$347.3K	10	14.7%
EGYPT

Who Are the Top Buyers of Itraconazole from Cohance Lifesciences Limited?

Buyer	Country	Value	Orders
NOVAMED FABRICACAO DE PRODUTOS	BRAZIL	$517.9K	13
MINT PHARMACEUTICALS INC	CANADA	$247.3K	8
ARROW PHARMACEUTICALS PTY LTD	AUSTRALIA	$246.6K	9
ARROW PHARMACEUTICALS PTY LIMITED	AUSTRALIA	$225.1K	7
NOVAMED FABRICACAO DE PRODUCTOS	BRAZIL	$200.0K	4
PT DEXA MEDICA	INDONESIA	$200.0K	4
QNB ALAHLI BANK	EGYPT	$179.7K	6
TO THE ORDER OF	INDONESIA	$133.8K	3
QNB ALAHLI	EGYPT	$89.9K	2
PT.INTERBAT	INDONESIA	$67.9K	2

Cohance Lifesciences Limited supplies Itraconazole to 18 buyers globally. The largest buyer is NOVAMED FABRICACAO DE PRODUTOS (BRAZIL), followed by MINT PHARMACEUTICALS INC (CANADA) and ARROW PHARMACEUTICALS PTY LTD (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Itraconazole Formulations Does Cohance Lifesciences Limited Export?

Product Description / Formulation	Value	Shipments
ITRACONAZOLE IR PELLETS 22%	$435.4K	13
ITRACONAZOLE IR PELLETS 21.74%	$275.4K	11
ITRACONAZOLE CAPSULES 100MG	$212.9K	5
ITRACONAZOLE IR PELLETS 22% W/W	$200.0K	4
ITRACONAZOLE IR PELLETS 22%KGS	$199.4K	4
COMMERCIAL INVOICE NO IN3600000533 DT 16 03 2023 ACTIVE PHARMACEUTICAL INGREDIENTS ITRACONAZOLE IR PELLETS 21 74	$100.0K	2
ITRACONAZOLE IR PELLETS 22	$97.3K	3
ITRACONAZOLE CAPSULES 100MG (30 CAPSULES)(QTY-13530)	$74.4K	3
ITRACONAZOLE CAPSULES 100MG (30 CAPSULES) (QTY:13260)NOS	$72.9K	3
TAX INV NO IN3600000501 DT 28 02 2023 PHARMACEUTICAL PRODUCT ITRACONAZOLE CAPSULES 100MG QTY 12983	$50.0K	1

Cohance Lifesciences Limited exports 30 distinct Itraconazole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ITRACONAZOLE IR PELLETS 22% with 13 shipments worth $435.4K.

How Does Cohance Lifesciences Limited Compare to Nearest Itraconazole Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	COHANCE LIFESCIENCES LIMITED ★	$3.5M	69	5	$50.0K
4	MICRO LABS LIMITED	$2.6M	128	11	$20.3K
6	AMNEAL PHARMACEUTICALS PRIVATE LIMITED	$1.9M	38	1	$50.0K

Cohance Lifesciences Limited ranks #1 among 285 Indian Itraconazole exporters. Average shipment value of $50.0K compared to the market average of $62.6K. The closest competitors by value are MICRO LABS LIMITED and AMNEAL PHARMACEUTICALS PRIVATE LIMITED.

Which Indian Ports Ship Itraconazole Exports?

Port	Shipments	% Share
SAHAR AIR	498	18.3%
DELHI AIR CARGO ACC (INDEL4)	415	15.2%
SAHAR AIR CARGO ACC (INBOM4)	345	12.7%
DELHI AIR	245	9.0%
NHAVA SHEVA SEA (INNSA1)	119	4.4%
Bombay Air	98	3.6%
Delhi Air	72	2.6%
JNPT/ NHAVA SHEVA SEA	56	2.1%

Geopolitical & Trade Policy Impact on Cohance Lifesciences Limited's Itraconazole Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Cohance Lifesciences. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and shipping costs. This situation necessitates strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost efficiency.

Conversely, the U.S.-China trade tensions have opened avenues for Indian exporters to capture market share previously dominated by Chinese manufacturers. Cohance's established presence and compliance with international standards position it favorably to meet the increased demand from U.S. importers seeking reliable alternatives.

The recent India-European Union Free Trade Agreement (FTA), concluded on January 27, 2026, eliminates tariffs on Indian pharmaceutical exports to the EU, including duties of up to 11% on pharmaceuticals. This development enhances Cohance's competitiveness in the European market, potentially boosting export volumes and revenues. (en.wikipedia.org)

Cohance Lifesciences Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for pharmaceutical exporters. The USFDA's issuance of a warning letter to Cohance's Hyderabad facility highlights the critical importance of adhering to Good Manufacturing Practices (GMP). While the immediate financial impact may be minimal due to the facility's limited contribution to U.S. revenues, the long-term implications on reputation and market access are significant. Proactive remediation and transparent communication with regulatory bodies are essential to restore and maintain compliance.

Additionally, the European Union's Falsified Medicines Directive (FMD) imposes stringent requirements on pharmaceutical imports. Cohance must ensure robust serialization and traceability measures to comply with these regulations, thereby safeguarding its access to the lucrative EU market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Itraconazole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cohance Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 69 individual customs records matching Cohance Lifesciences Limited exporting Itraconazole, covering 30 formulations to 5 countries via 18 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 123+ countries, 629+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Itraconazole

Itraconazole

Cohance Lifesciences Limited — Itraconazole Exporter Profile

Cohance Lifesciences Limited — Itraconazole Export Profile: Buyers & Destinations

Where Does Cohance Lifesciences Limited Export Itraconazole?

Who Are the Top Buyers of Itraconazole from Cohance Lifesciences Limited?

What Is India's Total Itraconazole Export Value and How Much Does Cohance Lifesciences Limited Contribute?

What Is the Average Shipment Value for Cohance Lifesciences Limited's Itraconazole Exports?

How Does Cohance Lifesciences Limited Compare to Other Indian Itraconazole Exporters?

What Itraconazole Formulations Does Cohance Lifesciences Limited Export?

Regulatory Requirements: Exporting Itraconazole to Key Markets

Brazil — ANVISA

Australia — TGA

How Does Cohance Lifesciences Limited Compare to Nearest Itraconazole Exporters?

Which Indian Ports Ship Itraconazole Exports?

Itraconazole — Export Intelligence Video

Geopolitical & Trade Policy Impact on Cohance Lifesciences Limited's Itraconazole Exports

Cohance Lifesciences Limited — Regulatory Compliance & Quality Standards

About Cohance Lifesciences Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Itraconazole Export Data from Cohance Lifesciences Limited

Itraconazole Stats

Company Overview

Top Products by Cohance Lifesciences Limited

Related Analysis

Need Detailed Export Data?

Data Source